Aims Cilostazol (CLS) has shown antidepressant effect in cardiovascular patients, post‐
stroke depression, and animal models through its neurotrophic and antiinflammatory …

Background Cilostazol, a phosphodiesterase-3 inhibitor, has been reported to improve
depressive-like behavior in experimental studies of depression. We investigated the safety …

Background: Cyclic nucleotide Phosphodiesterases (PDEs) are ubiquitously distributed in
mammalian tissues and play a major role in cell signaling by hydrolyzing cyclic Adenosine …

Abstract Rationale Phosphodiesterase 3 (PDE3) inhibitor cilostazol ameliorates negative
effects of cerebral hypoperfusion against cerebral ischemic injury through the …

This paper reports the efficacy and tolerability of the nicotinic channel modulator TC-5214
(dexmecamylamine) as adjunct therapy for patients with major depressive disorder who …

Introduction Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its
metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than …

Abstract Background and Purpose: To evaluate the citalopram in post-stroke depression
treatment, we compared its use to other selective serotonin reuptake inhibitors (SSRIs) …

Background: There is evidence for an association between major depressive disorder
(MDD) and both inflammatory and phosphodiesterase (PDE) pathways. This study aimed to …

Objectives This study aims to evaluate the safety and efficacy of escitalopram and sertraline
in post-stroke depression (PSD) patients, to provide more reliable therapeutics for …

Cilostazol is a phosphodiesterase-3 inhibitor and is known to have pleiotropic effects
including antiplatelet and vasodilatation effects and protective effects on endothelial cells …